Background Data on the efficacy of transcatheter edge-to-edge repair (TEER) in patients
with cardiogenic shock (CS) are limited. Objectives This study investigated the …

Review of the current literature fails to show significant mortality benefit with any specific
vasopressor or inotropic in CS patients. The upcoming DOREMI 2 and levosimendan versus …

Background Functional mitral regurgitation (MR) is an important clinical consideration in
patients with heart failure. Transcatheter edge-to-edge repair (TEER) has emerged as a …

Over the last two decades, implantable continuous flow left ventricular assist devices (LVAD)
have proven to be invaluable tools for the management of selected advanced heart failure …

Background Cardiogenic shock (CS) is associated with significant morbidity and mortality;
however, there are limited randomized data evaluating the association between sex and …

Background Inotropic support is widely used in the management of cardiogenic shock (CS).
Existing data on the incidence and significance of arrhythmic events in patients with CS on …

Background: Patients with cardiogenic shock (CS) and mitral regurgitation (MI) have a
prohibitive risk that contraindicates surgical treatment. Although the feasibility of …

Acute decompensated valvular disease encompasses a group of complex and challenging
conditions, which are often the primary reason for admission to the cardiac intensive care …

Valvular heart disease (VHD) is one of the most frequent causes of heart failure (HF) and is
associated with poor prognosis, particularly among patients with conservative management …

Cardiogenic shock (CS) remains paradoxically the cardiac condition with one of the highest
mortality rates yet the fewest therapies that improve outcomes. In an era that has seen vast …